NASDAQ:ACRS - Aclaris Therapeutics Stock Price, News & Analysis

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.05. The biotechnology company had revenue of $5.87 million for the quarter, compared to analysts' expectations of $5.77 million. Aclaris Therapeutics had a negative net margin of 979.65% and a negative return on equity of 81.40%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Aclaris Therapeutics.

4 Wall Street analysts have issued 12 month target prices for Aclaris Therapeutics' stock. Their predictions range from $5.00 to $34.00. On average, they expect Aclaris Therapeutics' stock price to reach $17.3333 in the next twelve months. This suggests a possible upside of 1,475.8% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aclaris Therapeutics.

Media headlines about ACRS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Aclaris Therapeutics.

Some companies that are related to Aclaris Therapeutics include Axovant Gene Therapies (AXGT), Adamas Pharmaceuticals (ADMS), Generex Biotechnology (GNBT), Bicycle Therapeutics (BCYC), REDHILL BIOPHAR/S (RDHL), American Brivision (Holding) (ABVC), Newron Pharmaceuticals (NWPHF), Hookipa Pharma (HOOK), BioXcel Therapeutics (BTAI), Sol Gel Technologies (SLGL), Applied Therapeutics (APLT), Aldeyra Therapeutics (ALDX), XOMA (XOMA), TAIWAN LIPOSOME/S (TLC) and Arcturus Therapeutics (ARCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Ocular Therapeutix (OCUL), TherapeuticsMD (TXMD), Exelixis (EXEL), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO) and BioDelivery Sciences International (BDSI).

Aclaris Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.21%), Man Group plc (4.97%), Rock Springs Capital Management LP (4.90%), Vanguard Group Inc. (4.52%), Renaissance Technologies LLC (1.70%) and D. E. Shaw & Co. Inc. (1.62%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

ACRS stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., AXA, Rice Hall James & Associates LLC, Cormorant Asset Management LP, Citadel Advisors LLC, BlackRock Inc., Bank of New York Mellon Corp and Morgan Stanley. View Insider Buying and Selling for Aclaris Therapeutics.

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Rock Springs Capital Management LP, Renaissance Technologies LLC, JPMorgan Chase & Co., Walleye Trading Advisors LLC, Walleye Trading LLC, Alambic Investment Management L.P. and Parametric Portfolio Associates LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.10.

Aclaris Therapeutics has a market capitalization of $45.50 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]